Temozolomide Production Cost Reports

The report provides a detailed analysis essential for establishing a Temozolomide production plant. It encompasses all critical aspects necessary for Temozolomide production, including the cost of Temozolomide production, Temozolomide plant cost, Temozolomide production costs, and the overall Temozolomide production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Temozolomide production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Temozolomide is an oral alkylating chemotherapy agent that is approved for treating glioblastoma multiforme. It is combined with radiotherapy as first-line therapy followed by maintenance monotherapy, and for refractory anaplastic astrocytoma in adults. It works by methylating DNA to inhibit cancer cell replication, with good blood-brain barrier penetration making it suitable for central nervous system malignancies.

It is also utilised in aggressive pituitary tumours, pituitary carcinomas, relapsed small cell lung cancer, metastatic melanoma, and neuroendocrine tumours. Also, research continues into its role in other solid tumours. Its common side effects include nausea, vomiting, constipation, fatigue, headache, loss of appetite, hair loss, and rash.

The market for Temozolomide is influenced by increasing incidences of brain tumours like gliomas and glioblastoma. The expanded healthcare investments and adoption of standardised oncology protocols fuel its demand. The growth of generics after patent expirations reduces costs and improves accessibility for hospitals, insurers, and public health programs.

The availability of reliable API suppliers with GMP certification, competitive pricing from producers, and disruptions from raw material shortages affects industrial Temozolomide procurement. The supply chain issues from tariffs, API reliance on China and India, and low supplier and buyer bargaining power affect market dynamics. Also, regional regulations and improving healthcare infrastructure further impact its sourcing strategies.

Raw Material for Temozolomide Production

According to the Temozolomide production plant project report, the key raw materials used in the production of Temozolomide include 5 aminoimidazole 4 carboxamide, N succinimidyl N′ methyl carbamate, diisopropylethylamine, and acetonitrile.

Production Process of Temozolomide

The extensive Temozolomide production cost report consists of the following major industrial production process:

1. From 5 aminoimidazole 4 carboxamide: The production process of Temozolomide involves a reaction between 5 aminoimidazole 4 carboxamide and N succinimidyl N′ methyl carbamate. This takes place in an aprotic polar solvent like acetonitrile in the presence of an alkyl amine base to give carbamoyl 5 aminoimidazole 4 carboxamide. This was then subjected to diazotisation with an alkali nitrite in the presence of an inorganic acid to give a crude mixture of Temozolomide and azaipoxanthine. This mixture is passed through a column of adsorbent polymeric resin to separate Temozolomide from azaipoxanthine. The product is recrystallised from a mixture of acetone and acidified water to get pure Temozolomide as the final product.

Temozolomide is an imidazotetrazine derivative chemotherapy prodrug that has the molecular formula of C6H6N6O2 and a molecular weight of 194.15 g/mol. It appears as a white to light tan or pink crystalline powder. It shows low water solubility and decomposes at 212 degree Celsius without melting. It has high thermal stability, while being lipophilic with a log logP value of -1.26 with a polar surface area of 108.17 Ų. It has one hydrogen bond donor and one rotatable bond for good oral bioavailability. It is stable at acidic pH but spontaneously hydrolyses at physiological and neutral pH to active MTIC via non-enzymatic breakdown, enhanced in alkaline tumour microenvironments. It requires refrigerated storage at 2-8degree Celsius to prevent degradation.